Chaudron J M, Beauduin M, Delwiche J P, Delannoy A, Luwaert R, Majois F, Lebacq E G, Pluygers E
Acta Cardiol. 1982;37(2):105-15.
The aim of this study was to detect the cardiotoxicity of Adriamycin (ADM) by the evolution of the systolic time intervals (STI). The PEP/LVET ratio represents an easy and reproducible index of myocardial function. The more important this increase, the greater the risk of developing heart failure. A significant correlation exists between the variation of this ratio and the total administered dose, but the correlation coefficient is low. A heart failure may appear for doses of ADM under 500 mg/m2 but it is preceded by an increase of the index. In the absence of a significant modification, the generally admitted maximum dose of 550 mg/m2 may be exceeded. In case of a ratio increase in excess of 0.08 it will be necessary to balance the potential benefits of treatment with the hazards of cardiac failure. The PEP/LVET ratio allows proceeding with the cytostatic treatment in increased security by selecting the patients at high risk for cardiac failure.
本研究的目的是通过收缩期时间间期（STI）的变化来检测阿霉素（ADM）的心脏毒性。PEP/LVET比值是心肌功能的一个简单且可重复的指标。该比值升高越显著，发生心力衰竭的风险就越大。该比值的变化与总给药剂量之间存在显著相关性，但相关系数较低。ADM剂量低于500mg/m²时可能出现心力衰竭，但在此之前该指标会升高。在无显著变化的情况下，可超过一般公认的最大剂量550mg/m²。如果该比值升高超过0.08，则有必要权衡治疗的潜在益处与心力衰竭的风险。PEP/LVET比值通过选择心力衰竭高危患者，能更安全地进行细胞毒性治疗。
